Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS

NovartisIn support of World MS Day, Novartis announced today the launch of the 7-Day Challenge to Live Like You for people with MS. The 7-Day Challenge to Live Like You, one of the first integrations of emerging technological trends by a pharmaceutical company, is simple: using wearable technology or accessing personal online systems that people use on a daily basis, including calendars, social media channels and fitness trackers, people with MS are invited to track their activities for seven days and gain valuable insights into what works best for their lifestyle. The 7-Day Challenge to Live Like You, which can be accessed via http://7daychallenge.tictrac.com, addresses the growing desire amongst the MS community to gather personalized information that will allow them to make decisions on how they can manage their lives with MS.

World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS and its impact on approximately 2.3 million people with MS[1] around the world. This year's World MS Day campaign focuses on 'access'. Importantly, the topic of access spans beyond access to treatment in MS. Increasingly, there is a need for access to relevant and personalized online information that allows people to utilize available tools in order to make adjustments that can help them to manage their MS in a way that best suits their lifestyle.

"Novartis is a proud supporter of World MS Day, and we recognize the value of providing access to personalized information for the MS community," said David Epstein, Division Head, Novartis Pharmaceuticals. "As part of our commitment to providing innovative solutions that go beyond treatments, we are delighted to announce the launch of the 7-Day Challenge to Live Like You, which will empower the MS community to gain valuable insights about themselves and their MS."

The 7-Day Challenge to Live Like You is a collaboration between Novartis and Tictrac, an innovative technology company with expertise in tracking user data and turning the data into unique perceptions (e.g. 'you're more active after a good night's sleep') that can help people with MS better understand their lifestyle in order to make small changes based on their new insights. Alongside the 7-Day Challenge to Live Like You, Novartis also recently launched Living Like You (www.livinglikeyou.com), an online resource community that features personal content for the MS community.

For people with MS, personalized information and tracking is essential because it can help with symptom management and take the guesswork out of what is and isn't working - and allow small changes that could help in achieving meaningful results. The tracking does not need to stop after the seven days are up; the 7-Day Challenge to Live Like You online tracking program will still be available to the MS community, to empower people with MS to continue to gain valuable insights about themselves and how to better manage their life with this debilitating disease.

About Living Like You
The Novartis-supported Living Like You (www.livinglikeyou.com) is an online resource community that features magazine-style content detailing the journey through the realities of life with MS by offering insights from people who live with the disease. Providing access to relevant information online is important as people with MS are up to three times more likely to be online compared to people with other diseases[2]; in fact, MS is mentioned online every 13 seconds.

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) that disrupts the normal functioning of the brain, optic nerve and spinal cord[3]. The evolution of MS results in an increasing loss of both physical (e.g. difficulty with walking) and cognitive (e.g. problems with mental tasks or memory) function[4]. This has a substantial negative impact on the approximately 2.3 million people worldwide affected by MS[1], a disease that begins in early adulthood, most often between the ages of 20 and 40[5].

The loss of physical and cognitive function is driven by two main types of damage that both contribute to widespread loss of neurons (nerve cells in the brain and spinal cord that transmit impulses): discrete inflammatory lesions, focal damage, in the brain that can clinically manifest as relapses; and ongoing, more diffuse damage that starts early in the disease and causes the progressive loss of brain tissue, including neurons, and over time is associated with both physical and cognitive problems[6]-[8].

About Novartis in Multiple Sclerosis
Novartis is committed to the research and development of new treatment options to offer the right treatment to the right patient at the right time, to meet patients' needs at every stage of disease with innovative and targeted drugs.

In addition to its ongoing development program for Gilenya in primary progressive MS (PPMS), pediatric MS and chronic inflammatory demyelinating polyneuropathy (CIPD), the Novartis MS portfolio includes Extavia® (interferon beta-1b for subcutaneous injection). Investigational compounds include BAF312 (siponimod), which is currently in Phase III clinical development and being developed as the first oral therapy for secondary progressive MS (SPMS), and VAY736, an anti-B-cell compound for MS that is currently being investigated in proof of concept studies. Novartis is also exploring the IL-17 pathway in MS.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

1. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1. Accessed May 2014. 2. Data on file. Novartis Pharmaceuticals. 'Multiple Sclerosis on the Social Web' social web audit. 3. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed May 2014. 4. http://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed May 2014. 5. http://emsp.org/multiple-sclerosis/ms-fact-sheet. Accessed May 2014. 6. Filippi M et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012 Apr;11(4):349-60. 7. Kutzelnigg A et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 Nov;128(Pt 11):2705-12. 8. Sormani MP, Arnold DL & De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43-9.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]